Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment

Table 2 Distribution of CYP2D6 genotype and predicted phenotype by different ethnic groups

	Ethnicity
*CYP2D6*predicted phenotype/genotype	Caucasian	Latina/Hispanic	AA/Black	Asian	Pacific Islander	Other/mixed	Declined/missed	Total N (%)
Ultra-rapid (UM)	8 (5%)	1 (7%)	0	1 (2%)	0	0	0	10 (4%)
1/1 × N	5	0	0	0	0	0	0	5
1/2 × N	1	1	0	0	0	0	0	2
2/1 × N	1	0	0	1	0	0	0	2
2/2 × N	1	0	0	0	0	0	0	1
Extensive (EM)	131 (79%)	9 (65%)	2 (100%)	36 (64%)	1 (100%)	3 (100%)	3 (100%)	185 (76%)
1/1	19	2	1	2	1	1	0	26
1/2	20	0	0	5	0	0	0	25
1/3	2	0	0	0	0	0	0	2
1/4	23	1	0	1	0	0	1	26
1/5	3	0	0	1	0	1	0	5
1/6	1	0	0	0	0	0	0	1
1/9	4	2	0	0	0	0	0	6
1/10	1	0	0	15	0	0	0	16
1/17	1	0	1	0	0	0	0	2
1/29	0	0	0	0	0	0	1	1
1/35	2	0	0	0	0	0	0	2
1/41	16	1	0	1	0	0	0	18
1 × N/5	1	0	0	0	0	0	0	1
1 × N/10	0	0	0	1	0	0	0	1
2/2	5	0	0	0	0	0	0	5
2/4	11	1	0	0	0	0	1	13
2/5	1	0	0	0	0	0	0	1
2/9	1	0	0	0	0	0	0	1
2/10	0	1	0	10	0	0	0	11
2/35	3	0	0	0	0	0	0	3
2/41	5	0	0	0	0	0	0	5
2/41 × N	1	0	0	0	0	0	0	1
2 × N/4	1	0	0	0	0	0	0	1
2 × N/9	1	0	0	0	0	0	0	1
3/35	1	0	0	0	0	0	0	1
4/35	5	0	0	0	0	0	0	5
5/35	0	1	0	0	0	0	0	1
10/35	1	0	0	0	0	0	0	1
17/35	0	0	0	0	0	1	0	1
35/41	1	0	0	0	0	0	0	1
35/41 × N	1	0	0	0	0	0	0	1
Intermediate (IM)	15 (9%)	2 (14%)	0	15 (27%)	0	0	0	32 (13%)
4/9	1	0	0	0	0	0	0	1
4/10	2	0	0	0	0	0	0	2
4/17	1	0	0	0	0	0	0	1
4/41	6	1	0	0	0	0	0	7
5/10	1	0	0	2	0	0	0	3
10/10	0	0	0	13	0	0	0	13
10/41	2	0	0	0	0	0	0	2
29/41	0	1	0	0	0	0	0	1
41/41	2	0	0	0	0	0	0	2
Poor (PM)	10 (6%)	2 (14%)	0	1 (2%)	0	0	0	13 (5%)
3/4	1	0	0	0	0	0	0	1
4/4	7	0	0	1	0	0	0	8
4/5	0	2	0	0	0	0	0	2
4/6	1	0	0	0	0	0	0	1
4/7	1	0	0	0	0	0	0	1
No genotype	2 (1%)	0	0	3 (5%)	0	0	0	5 (2%)
Total	166	14	2	56	1	3	3	245

AA, African American; EM, extensive metabolizer; IM, intermediate metabolizer; N, number of participants in the study; PM, poor metabolizer; UM, ultra-rapid metabolizer.

ISSN: 1756-994X